Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28487513 | 0.86 | ALDH1A1 (0.52) | — | |
| SCHEMBL13790659 | 0.86 | ALDH1A1 (0.52) | — | |
| SCHEMBL16958509 | 0.84 | — | — | |
| SCHEMBL505097 | 0.82 | HCAR1 (0.53) | — | |
| SCHEMBL5222697 | 0.81 | CES2 (0.45) | — | |
| Hydrochloric Acid SCHEMBL6524503 | 0.81 | HCAR1 (0.52) | — | |
| SCHEMBL2825638 | 0.81 | PARP1 (0.46) | — | |
| SCHEMBL10596241 | 0.81 | CES2 (0.45) | — | |
| SCHEMBL23384719 | 0.80 | — | — | |
| SCHEMBL20646737 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0195396-B1 | 5-FLUOROBENZONITRILE DERIVATIVES AND PHARMACOLOGICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF FOR INCREASING THE LEAN MEAT TO FAT RATIO, AND/OR ENHANCING THE GROWTH RATE OF WARM-BLOODED ANIMALS | AMERICAN CYANAMID COMPANY (US) | 1989-03-01 | — | — | EP | claimed |
| EP-0195396-A1 | 5-Fluorobenzonitrile derivatives and pharmacologically acceptable acid addition salts thereof for increasing the lean meat to fat ratio, and/or enhancing the growth rate of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1986-09-24 | — | — | EP | claimed |
| EP-4739669-A1 | SODIUM CHANNEL BLOCKERS | Novartis AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| CN-119546304-A | Salts of SOS1 inhibitors | 米拉蒂治疗公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250059182-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-02-20 | — | — | US | disclosed |
| CN-119462626-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250034108-A1 | SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2025-01-30 | — | — | US | disclosed |
| WO-2025011450-A1 | SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2025-01-16 | — | — | WO | disclosed |
| CN-101977908-A | (pyrazolyl carbonyl) imidazolidinone derivatives for the treatment of retroviral diseases | AICURIS GMBH & CO KG | 2011-02-16 | — | — | CN | disclosed |
| EP-2254885-A1 | (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES | AiCuris GmbH & Co. KG (DE) | 2010-12-01 | — | — | EP | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009115213-A1 | (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009115213-A1 | (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2009-09-24 | — | — | WO | disclosed |
| EP-0195396-B1 | 5-FLUOROBENZONITRILE DERIVATIVES AND PHARMACOLOGICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF FOR INCREASING THE LEAN MEAT TO FAT RATIO, AND/OR ENHANCING THE GROWTH RATE OF WARM-BLOODED ANIMALS | AMERICAN CYANAMID COMPANY (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4614746-A | 5-fluorobenzonitrile derivatives for increasing the lean meat to fat ratio and/or enhancing the growth rate of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1986-09-30 | — | — | US | disclosed |
| EP-0195396-A1 | 5-Fluorobenzonitrile derivatives and pharmacologically acceptable acid addition salts thereof for increasing the lean meat to fat ratio, and/or enhancing the growth rate of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1986-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034108-A1 | SODIUM CHANNEL BLOCKERS | SCN5A, SCN2B, SCN1B | VNN1 1948/4885 |
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | SOS1, SOS2, SOST | VNN1 4448/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | VNN1 4142/4885 |
| US-20250059182-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | VNN1 4266/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | VNN1 4142/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | VNN1 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.